Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
The Senior Director, National and Strategic Accounts will be a key member of the Market Access leadership team and will be responsible for the development of the Market Access Payer strategic plan and vision for business opportunities in various national and regional markets to support the launch of first product, palazestrant, along with future indications and additional therapies.
What they're looking for
- 15+ years of bio/pharmaceutical experience required with a key understanding of current US pharmaceutical payer models
- 10+ years of direct US Payer and/or Provider Account management experience (NAM, RAM, KAM))
- 5+ years of people management experience
- Previous experience working in the pharmaceutical or biotech industry is required with strong preference in Oncology
- Seasoned National Accounts leader with Oncology experience preferred
- In depth knowledge of pharmaceutical manufacturer compliance requirements, patient confidentiality (HIPAA regulations), product reimbursement and product access
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs · Remote jobs